Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
16 Septembre 2024 - 10:06PM
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or
the "Company"), a clinical-stage biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, today announced the
publication of an international patent application under the Patent
Cooperation Treaty (“PCT”) for its pioneering combination therapy
of Ibogaine and N-Acylethanolamines.
Ibogaine, a key compound derived from the root of Tabernanthe
iboga, a shrub native to West and Central Africa, has shown promise
in human clinical trials for treating opioid use disorder (OUD),
cocaine use disorder (CUD), and other substance use disorders
(SUD). As a result, Ibogaine is considered a potentially effective
anti-addiction agent.
The patent application follows innovative developments from
Clearmind’s successful collaboration with SciSparc Ltd. (Nasdaq:
SPRC) (“SciSparc”), a clinical-stage specialty pharmaceutical
company focused on treatments for central nervous system disorders.
Together, the two companies are researching innovative combination
therapies that integrate psychedelic compounds with the
N-Acylethanolamines family, including Palmitoylethanolamide
(PEA).
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented: “The
publication of this patent highlights Clearmind’s commitment to
leadership in the psychedelics space through building a diverse
patent portfolio, featuring technologies with varying timelines to
market. Most importantly, we aim to provide safe and effective
solutions for mental health conditions that currently have unmet
needs. While treatments with Ibogaine are generally considered safe
under proper medical supervision, there have been reports of
fatalities or adverse events associated with the ingestion of iboga
plant material or Ibogaine. We believe that combining Ibogaine with
Palmitoylethanolamide will further enhance the efficacy and safety
of this promising therapy.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech
company focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company’s intellectual portfolio currently consists of
nineteen patent families including 29 granted patents. The Company
intends to seek additional patents for its compounds whenever
warranted and will remain opportunistic regarding the acquisition
of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the
symbol "CMND" and the Frankfurt Stock Exchange under the symbol
“CWY0.”
About SciSparc Ltd.
SciSparc Ltd. (SPRC) is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. SciSparc’s focus is on creating and
enhancing a portfolio of technologies and assets based on
cannabinoid pharmaceuticals. With this focus, the Company is
currently engaged in the following drug development programs based
on THC and/or non-psychoactive cannabidiol: SCI-110 for the
treatment of Tourette Syndrome, for the treatment of Alzheimer's
disease and agitation; and SCI-210 for the treatment of autism and
status epilepticus. The Company also owns a controlling interest in
a subsidiary whose business focuses on the sale of hemp seeds’
oil-based products on the Amazon.com Marketplace.
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relationsinvest@clearmindmedicine.com
Telephone: (604) 260-1566US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses Clearmind’s commitment
to be a leader in the psychedelics space by creating a diverse
patent portfolio, which contains various technologies with
different times to market, but more importantly provides
efficacious and safe solutions to various mental health conditions
with unmet needs. The Company cannot assure that any patent will
issue as a result of a pending patent application or, if issued,
whether it will issue in a form that will be advantageous to the
Company. Forward-looking statements are not historical facts, and
are based upon management’s current expectations, beliefs and
projections, many of which, by their nature, are inherently
uncertain. Such expectations, beliefs and projections are expressed
in good faith. However, there can be no assurance that management’s
expectations, beliefs and projections will be achieved, and actual
results may differ materially from what is expressed in or
indicated by the forward-looking statements. Forward-looking
statements are subject to risks and uncertainties that could cause
actual performance or results to differ materially from those
expressed in the forward-looking statements. For a more detailed
description of the risks and uncertainties affecting the Company,
reference is made to the Company’s reports filed from time to time
with the Securities and Exchange Commission (“SEC”), including, but
not limited to, the risks detailed in the Company’s annual report
on Form 20-F for the fiscal year ended October 31, 2023 filed with
the SEC. Forward-looking statements speak only as of the date the
statements are made. The Company assumes no obligation to update
forward-looking statements to reflect actual results, subsequent
events or circumstances, changes in assumptions or changes in other
factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update
one or more forward-looking statements, no inference should be
drawn that the Company will make additional updates with respect
thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Clearmind is not
responsible for the contents of third-party websites.
Clearmind Medicine (NASDAQ:CMND)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Clearmind Medicine (NASDAQ:CMND)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024